Wegovy reduces cardiovascular risks in phase 3 trial

Novo Nordisk's Wegovy, a weight loss drug, showed a 20 percent reduction in major adverse cardiovascular events in a phase 3 trial, the drugmaker said Aug. 8.

For five years, the company has researched how more than 17,000 adults who are overweight or obese and have cardiovascular disease reacted to Wegovy or a placebo. The trial tested the drug's 2.4 milligram solution — the highest dosage approved for Wegovy after weekly increases from 0.25 milligrams.

The drug reduced cardiovascular events by 20 percent compared to the placebo group, Novo Nordisk said, and the solution was safe and effective.

The company said it plans to file approval documents in 2023 in seeking broader indication for the approved drug.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars